Scilex Holding (SCLX) Operating Margin (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Operating Margin of 374.06% for Q1 2026, up 18390.0% year-over-year from N/an in Q1 2025, and up 83.7% quarter-over-quarter from 2295.25% in Q4 2025.
Scilex Holding (SCLX) Operating Margin (2022 - 2026) Analysis & Trends
Scilex Holding's Operating Margin history runs 5 years deep, the most recent figure standing at 374.06% for Q1 2026.
- In Q1 2026, Operating Margin rose 18390.0% year-over-year to 374.06%; the TTM figure through Mar 2026 stood at 1033.39% (down 85235.0% YoY), while the FY2025 annual figure was 1141.94%, down 99459.0% from the prior year.
- Operating Margin for Q1 2026 stood at 374.06%, up from 2295.25% in the prior quarter.
- The five-year high for Operating Margin was 93.31% in Q3 2022, with the low at 2295.25% in Q4 2025.
- The 5-year median for Operating Margin is 181.32% (2023), against an average of 428.13%.
- The sharpest annual moves came in 2024 and 2025: Operating Margin surged 24559 bps in 2024, then tumbled 210492 bps in 2025.
- Scilex Holding's Operating Margin stood at 165.63% in 2022, then rose by 18 bps to 136.23% in 2023, then slumped by 40 bps to 190.33% in 2024, then tumbled by 1106 bps to 2295.25% in 2025, then surged by 84 bps to 374.06% in 2026.
- Business Quant data shows SCLX's Operating Margin at 374.06% in Q1 2026, 2295.25% in Q4 2025, and 1766.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 5.72% |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -385.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -2,295.25% |
| Sep 30, 2025 | -1,766.21% |
| Jun 30, 2025 | -207.23% |
| Mar 31, 2025 | -557.96% |
| Dec 31, 2024 | -190.33% |
| Sep 30, 2024 | -137.97% |
| Jun 30, 2024 | -95.44% |
| Mar 31, 2024 | -178.96% |
| Dec 31, 2023 | -136.23% |
| Sep 30, 2023 | -383.56% |
| Jun 30, 2023 | -181.32% |
| Mar 31, 2023 | -240.72% |
| Dec 31, 2022 | -165.63% |
| Sep 30, 2022 | -93.31% |
| Jun 30, 2022 | -144.73% |
| Mar 31, 2022 | -129.27% |